I recently had the pleasure of speaking with Claus Zieler, Chief Commercial Officer at Astellas and a member of the board of EFPIA. He spoke with me about his career, as well as improvements he’d like to see in the regulatory framework in Europe.
In Europe, new medicines are often very slow to come to market because of fragmentation. The region is also no longer seen as competitive when it comes to new clinical trials. “Companies are right to ask: why should I perform this research or development in Europe if Europe doesn't give me access to a database, or makes it very slow for me to start a trial?” Zieler explained.
We’ve published articles based on the conversation, but in the digital age many of you may prefer to watch a video. You can check out the video interview below.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
